B. anthracis: passive immunization with anticapsular mAb
B. anthracis: passive immunization with anticapsular mAb
批准号:
8197102
负责人:
Thomas R Kozel
金额:
$54.17万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-06-01 至 2013-11-30
关键词:
AccountingActive ImmunizationAffinityAnthrax VaccinesAnthrax diseaseAntibodiesAntibody-mediated protectionAntigensBacillus anthracisBacteriaBiologicalCharacteristicsConjugate VaccinesDecision MakingDevelopmentDiseaseDrug FormulationsEffector CellEncapsulatedEndemic DiseasesEvaluationEventExhibitsFamilyFc ReceptorGenerationsGlutamic AcidGoalsGrantHealthHumanIgG1IgG3Immune responseImmunizationImmunochemistryImmunoglobulin Class SwitchingImmunoglobulin GImmunoglobulin Variable RegionIn VitroInfectionLungModelingMolecularMonoclonal AntibodiesMusOryctolagus cuniculusPassive ImmunizationPathogenesisPathologyPolysaccharidesPreventionProbabilityRoleSeptic ToxemiaSignal TransductionTestingVaccinationVaccinesVariantVirulenceantibody engineeringbasecapsulechimeric antibodydesignefficacy testinghumanized antibodyin vivopolypeptideresponsevaccine developmentvaccine efficacy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Bacillus anthracis is surrounded by an antiphagocytic capsule that is composed of poly-?-D-glutamic acid (? DPGA). The ? DPGA capsule is an attractive target for immunoprotection because it is essential for virulence and offers a second target for vaccine development in addition to the currently targeted protective antigen. Indeed, there is considerable potential for synergy in a dual target strategy. However, targeting the B. anthracis capsule for active or passive immunization will require an understanding of how capsular antibodies mediate protection and an identification of in vivo correlates of protection. Such information is particularly important with a select agent for which there is little naturally occurring disease that would allow for evaluation of active or passive immunization efficacy. Six monoclonal antibodies (mAbs) reactive with ? DPGA were generated and studied during the current grant period. Most were of the IgG3 subclass. Five were protective; one was not. IgG subclass switch families (IgG3 -> IgG1 -> IgG2b -> IgG2a) were generated from two of the protective mAbs. Despite having identical variable regions, the IgG1, IgG2b and IgG2a variants failed to protect. Features common to all protective mAbs were i) the IgG3 subclass, ii) high intrinsic affinity, and iii) and the ability of the antibody to structurally remodel the capsular outer edge. The overall goal of this competing renewal is to understand, at a molecular level, why one ? DPGA mAb is protective and another ? DPGA mAb fails to protect. The overall hypothesis is that the IgG subclass- dependent ability of an antibody to protect is dependent on i) the ability of the mAb to remodel the capsular edge in an affinity-dependent manner, ii) the inherent biological activities of each subclass, and iii) the response of effector cells to signaling via activation or inhibitory Fc receptors. This hypothesis will be examined in five Specific Aims that will examine the roles of IgG subclass and affinity as independent variables that influence protection. Specific Aim 1 will identify the IgG heavy chain domains that influence mAb affinity. Specific Aim 2 will assess the roles of IgG subclass and affinity in protection. Specific Aim 3 will evaluate synergy between mAbs of different IgG subclasses. Aim 4 will examine the role of FcR signaling in protection. Finally, Aim 5 will utilize information generated in Aims 1-4 to optimize parameters for prevention and treatment of murine and rabbit pulmonary anthrax. PUBLIC HEALTH RELEVANCE: This project will determine the mechanism for protection by antibodies directed toward the outer coat of Bacillus anthracis. This information will be critical to decisions made in formulation of a new-generation anthrax vaccine or the design of genetically engineered antibodies to treat anthrax in humans.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Constant domains influence binding of mouse-human chimeric antibodies to the capsular polypeptide of Bacillus anthracis.
恒定结构域影响小鼠-人嵌合抗体与炭疽芽孢杆菌荚膜多肽的结合。
DOI:
10.4161/viru.25711
发表时间:
2013
期刊:
Virulence
影响因子:
5.2
作者:
[Hubbard,MarkA, Thorkildson,Peter, Kozel,ThomasR, AuCoin,DavidP]
通讯作者:
AuCoin,DavidP
DOI:
10.1371/journal.ppat.1003306
发表时间:
2013
期刊:
PLoS pathogens
影响因子:
6.7
作者:
[Hovenden M, Hubbard MA, Aucoin DP, Thorkildson P, Reed DE, Welch WH, Lyons CR, Lovchik JA, Kozel TR]
通讯作者:
Kozel TR
Multiplexed rapid immunoassay for invasive fungal disease
-
批准号:10463659
-
项目类别:
-
资助金额:$65.39万
-
财政年份:2020
-
负责人:Thomas R Kozel
-
依托单位:
Multiplexed rapid immunoassay for invasive fungal disease
-
批准号:10116147
-
项目类别:
-
资助金额:$70.26万
-
财政年份:2020
-
负责人:Thomas R Kozel
-
依托单位:
Multiplexed rapid immunoassay for invasive fungal disease
-
批准号:10269054
-
项目类别:
-
资助金额:$68.15万
-
财政年份:2020
-
负责人:Thomas R Kozel
-
依托单位:
Biomarker discovery for immunodiagnosis of invasive candidiasis
-
批准号:8677688
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2013
-
负责人:Thomas R Kozel
-
依托单位:
Biomarker discovery for immunodiagnosis of invasive candidiasis
-
批准号:8592083
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2013
-
负责人:Thomas R Kozel
-
依托单位:
Immunoassay for capsular antigen for rapid diagnosis of anthrax
-
批准号:8460572
-
项目类别:
-
资助金额:$63.83万
-
财政年份:2011
-
负责人:Thomas R Kozel
-
依托单位:
Immunoassay for capsular antigen for rapid diagnosis of anthrax
-
批准号:8076076
-
项目类别:
-
资助金额:$71.81万
-
财政年份:2011
-
负责人:Thomas R Kozel
-
依托单位:
Immunoassay for capsular antigen for rapid diagnosis of anthrax
-
批准号:8648999
-
项目类别:
-
资助金额:$89.37万
-
财政年份:2011
-
负责人:Thomas R Kozel
-
依托单位:
Immunoassay for capsular antigen for rapid diagnosis of anthrax
-
批准号:8828064
-
项目类别:
-
资助金额:$49.8万
-
财政年份:2011
-
负责人:Thomas R Kozel
-
依托单位:
Immunoassay for capsular antigen for rapid diagnosis of anthrax
-
批准号:8252139
-
项目类别:
-
资助金额:$62.04万
-
财政年份:2011
-
负责人:Thomas R Kozel
-
依托单位:
Antigenemia immunoassay for point of care dianostic melioidosis
-
批准号:7675197
-
项目类别:
-
资助金额:$27.97万
-
财政年份:2009
-
负责人:Thomas R Kozel
-
依托单位:
PGA antigenemia for early diagnosis of anthrax
-
批准号:7555622
-
项目类别:
-
资助金额:$83.39万
-
财政年份:2005
-
负责人:Thomas R Kozel
-
依托单位:
PGA antigenemia for early diagnosis of anthrax
-
批准号:6818019
-
项目类别:
-
资助金额:$55.22万
-
财政年份:2005
-
负责人:Thomas R Kozel
-
依托单位:
PGA antigenemia for early diagnosis of anthrax
-
批准号:7163709
-
项目类别:
-
资助金额:$54.37万
-
财政年份:2005
-
负责人:Thomas R Kozel
-
依托单位:
PGA antigenemia for early diagnosis of anthrax
-
批准号:7356407
-
项目类别:
-
资助金额:$82.2万
-
财政年份:2005
-
负责人:Thomas R Kozel
-
依托单位:
PGA antigenemia for early diagnosis of anthrax
-
批准号:7005824
-
项目类别:
-
资助金额:$54.41万
-
财政年份:2005
-
负责人:Thomas R Kozel
-
依托单位:
B. anthracis: passive immunization with anticapsular mAb
-
批准号:7739446
-
项目类别:
-
资助金额:$52.67万
-
财政年份:2004
-
负责人:Thomas R Kozel
-
依托单位:
B. anthracis: passive immunization with anticapsular mAb
-
批准号:7587914
-
项目类别:
-
资助金额:$52.67万
-
财政年份:2004
-
负责人:Thomas R Kozel
-
依托单位:
B. anthracis:passive immunization with anticapsular mAb
-
批准号:7069101
-
项目类别:
-
资助金额:$46.98万
-
财政年份:2004
-
负责人:Thomas R Kozel
-
依托单位:
B. anthracis:passive immunization with anticapsular mAb
-
批准号:6897804
-
项目类别:
-
资助金额:$44.77万
-
财政年份:2004
-
负责人:Thomas R Kozel
-
依托单位:
海外基金